Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preliminary Efficacy and Safety of Pegylated Interferon Alpha-2b Combined With Targeted Immunotherapy in Patients With Unresectable Advanced Chronic Hepatitis B-related Hepatocellular Carcinoma: a Prospective, Real-world Study

NCT07769827 is registered in ClinicalTrials.gov with Jinling Hospital, China as lead sponsor.

NCT NCT07769827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07769827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preliminary Efficacy and Safety of Pegylated Interferon Alpha-2b Combined With Targeted Immunotherapy in Patients With Unresectable Advanced Chronic Hepatitis B-related Hepatocellular Carcinoma: a Prospective, Real-world Study
Lead sponsor
Jinling Hospital, China
Phase
Not applicable
Overall status
Recruiting
Start date
December 26, 2025
Completion date
March 1, 2029
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hbv-hcc, unresectable advanced hbv-related liver cancer